title: [Clinical investigation on target value of T>MIC in carbapenems].
abstract: There have been few clinical reports on pharmacokinetics-pharmacodynamics (PK-PD) theory, although many basic or fundamental researches on appropriate use for the antimicrobials based on the PK-PD theory have been performed. We evaluated the target T>MIC values on meropenem and biapenem which have been obtained by basic researches. While we investigated whether the target T>MIC values were also useful for anaerobic infections. Clinical and bacteriological efficacies of meropenem and biapenem were about 70% in T>MIC over 25% or over 80% in T>MIC over 30%. When monomicrobial infections by anaerobes were occurred as abscesses, there have been no correlation between target T>MIC values and clinical effect. When polymicrobial infections between aerobes and anaerobes were occurred, we have achieved over 90% clinical efficacy when over 20% T>MIC values. These results supported the data by Craig, W. A. and Drusano, G. L. The regimen based on PK-PD theory would be useful in clinical practice including against anaerobic infections.
authors.affiliation: Department of Infection Control and Prevention, Aichi Medical University.
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Mikamo
authors.forename: Yuka
authors.initials: Y
authors.lastname: Yamagishi
authors.forename: Kaori
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kunitomo
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D001420:Bacteria, Aerobic / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy*; D015780:Carbapenems / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D006801:Humans; D000077731:Meropenem; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013845:Thienamycins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem; C065257:biapenem